Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rucaparib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,809Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    The pharma& Group Partners With Tolmar to Promote Rubraca® for mCRPC
    The pharma& Group Partners With Tolmar to Promote Rubraca® for mCRPC

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-pharma-group-enters-into-an-exclusive-promotional-agreement-with-tolmar-inc-to-promote-rubraca-rucaparib-in-the-us-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-302256330.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share
    FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
    FDA sends CRL to Clovis in last-gasp bid for Rubraca nod

    06 Jun 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fda-rejects-clovis-long-shot-bid-approval-rubraca

    Kevin Dunleavy FIERCE PHARMA
    06 Jun 2023
    Share Share
    With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M
    With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M

    08 Apr 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/bankruptcy-clovis-sells-remaining-assets-including-rubraca-70m

    Kevin Dunleavy FIERCE PHARMA
    08 Apr 2023
    Share Share
    Clovis reveals even more regulatory troubles for Rubraca
    Clovis reveals even more regulatory troubles for Rubraca

    13 Feb 2023

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ema-requests-more-data-fda-spots-potential-harm-clovis-limps-through-rubraca-apps-amid

    Angus Liu FIERCE PHARMA
    13 Feb 2023
    Share Share
    Embattled Clovis Oncology Files for bankruptcy, Sells pipeline asset to Novartis
    Embattled Clovis Oncology Files for bankruptcy, Sells pipeline asset to Novartis

    13 Dec 2022

    // Alex Keown BIOSPACE

    https://www.biospace.com/article/embattled-clovis-oncology-files-for-chapter-11-sells-radioligand-therapeutic-to-novartis/

    Alex Keown BIOSPACE
    13 Dec 2022
    Share Share
    Cancer drugmaker Clovis files for bankruptcy, hit by falling sales
    Cancer drugmaker Clovis files for bankruptcy, hit by falling sales

    12 Dec 2022

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-drugmaker-clovis-files-chapter-11-bankruptcy-2022-12-12/

    REUTERS
    12 Dec 2022
    Share Share